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Abstract: Coordination compounds of 5-chloroacetamido-1,3,4-thiadiazole-2-sulfonamide (Hcaz)
with V(IV), Cr(lll), Fe(ll), Co(ll), Ni(ll) and Cu(ll) have been prepared and characterized by standard
procedures (spectroscopic, magnetic, EPR, thermogravimetric and conductimetric
measurements). Some of these compounds showed very good in vitro inhibitory properties against
three physiologically relevant carbonic anhydrase (CA)isozymes, i.e., CA I, II, and IV. The
differences between these isozymes in susceptibility to inhibition by these metal complexes is
discussed in relationship to the characteristic features of their active sites, and is rationalized in
terms useful for developing isozyme-specific CA inhibitors.
Introduction
1,3,4-Thiadiazole-2-sulfonamide derivativesza played a critical role for the development of
several important classes of pharmacological agents, such as the diuretics with saluretic action,
4
benzothiadiazine and high-ceiling diuretics,
46 and the antiglaucoma drugs with carbonic anhydrase
(CA) inhibitory action among others.
7 The 4Prototype of all these drugs was constituted by
acetazolamide 1, the first non-mercurial diuretic, used for more than 45 years in clinical medicine as
7 10 diuretic, antiglaucoma, antiepileptic and antiulcer compound. It is still used nowadays, mainly as
a diagnostic tool in NMR imaging, and in many physiological studies.
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The success of acetazolamide in clinical medicine fostered much research in the synthesis
and pharmacological evaluation of many 1,3,4-thiadiazole-2-sulfonamide derivatives.
46 Thus,
benzolamide 2 was approved in USA as a drug, and several studies showed its efficiency in
emphysema,
17 but its status is nowadays that of an orphan drug, although its clinical value has never
been contested. Benzolamide is also widely used in many renal and pulmonary physiological
studies.a’8 The halogeno-acetazolamides, such as chloroacetazolamide 3 led to the development
of topical antiglaucoma sulfonamide CA inhibitors,
TM which recently introduced in clinics,
9,o constituted one of the best treatments of open-angle glaucoma.
Metal complexes of sulfonamides of type 1-3 started to be investigated only in the last 10
years, with the report of Borras’ group of the first X-ray crystallographic structure of some
acetazolamide complexes.
1 It has been thereafter proved by our group that such compounds
possess unexpectedly strong inhibitory properties against the zinc enzyme carbonic anhydrase
(CA, EC 4.2.1.1 ), and this finding opened new vistas in the search of isozyme-specific inhibitors, as
16.26 well as other types of clinical/diagnostic applications of such enzyme inhibitors.
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Thus, we have recently reported the potent intraocular pressure (lOP) lowering effects of
metal complexes of sulfonamide CA inhibitors such as chloracetazolamide 3, the adamantyl-
carboxamido compound 4, as well as other classes of heterocyclic sulfonamides. Metal ions that
generally led to potent such activities were Zn(ll) and Cu(ll).’z’ The most remarkable aspect of
these studies was that even when the sulfonamide from which the metal complexes were prepared
was ineffective topically as an lOP lowering agent, its metal complexes possessed powerful such
properties.’’ It has been proved that the observed effects are due to inhibition of at least two CA
isozymes (CA II and IV) present within ciliary processes of the eye in the experimental animals
used. Thus, these types of compounds constitute interesting candidates for developing novel
antiglaucoma drugs.
Since many CA isozymes are presently known,e and not all of them were tested for
interaction with the metal complexes of heterocyclic sulfonamides, it appeared of interest to study
in more details this phenomenon which might be critical for the design of more effective and
specific, eventually isozyme-specific CA inhibitors. In this paper we report the preparation of metal
complexes of the conjugate base of sulfonamide 3, containing the following metal ions: V(IV),
Cr(lll), Fe(ll), Co(ll), Ni(ll) and Cu(ll). The obtained complexes have been characterized by standard
procedures (spectroscopic, EPR, magnetic, thermogravimetric and conductimetric measurements)
and assayed for inhibition of three CA isozymes, i.e., CA I, II, and IV.
aterials and Methods
IR spectra were recorded on a Perkin-Elmer 16PC FTIR instrument, in the range 200-4000
cm, in KBr pellets. Solution electronic spectra were recorded with a Cary 3 spectrophotometer
interfaced with a P.C. Electronic spectra were obtained by the diffuse reflectance technique in MgO
as reference, with a Perkin Elmer Lambda 15 apparatus, in the range 200-900 cm. Conductimetric
measurements were done in DMF solutions, at 25C (concentrations of mM of complex) with a
Fisher conductimeter. EPR spectra were recorded on a Varian E-9 spectrometer at room
temperature, in crystalline powder. The field was calibrated using crystalline diphenylpicrylhydrazyl
(g 2.0036). Magnetic susceptibility measurements were carried out at room temperature with a
fully automated AZTEC DSM8 pendulum-type susceptometer. Mercury(ll) tetrakis-
(thiocyanato)cobaltate(ll) was used as a susceptibility standard. Corrections for the diamagnetism
were estimated from Pascal’s constants. Elemental analyses were done by combustion for C,H,N
with an automated Carlo Erba analyzer, and gravimetrically for the metal ions, and were + 0.4% of
the theoretical values. Thermogravimetric measurements were done in air, at a heating rate of
10C/min., with a Perkin Elmer 3600 thermobalance.
Chloracetazolamide was prepared as described in a previous paper, whereas other
sulfonamides used as standards in the enzymatic assays were commercially available from Aldrich,
Sigma or Acros. Metal salts (iron(Ill) chloride dihydrate; vanadyl(IV) sulfate dihydrate; cobalt(ll)
chloride hexahydrate; cobalt(ll) acetate; nickel(ll) chloride; chromium(Ill) chloride hexahydrate and
copper(ll) chloride and acetate dihydrate) were from E. Merck.
Human CA and CA II cDNAs were expressed in Escherichia coil strain BL21 (DE3) from the
plasmids pACA/HCA and pACA/HCA II (the two plasmids were a gift from Prof. Sven Lindskog,
Umea University, Sweden). Cell growth conditions were those described by Lindskog’s group,
and enzymes were purified by affinity chromatography according to the method of Khalifah et al.
Enzyme concentrations were determined spectrophotometrically at 280 nm, using a molar
absorptivity of 49 mM. cm for CA and 54 mM.cm for CA II, respectively, based on Mr 28.85
kDa for CA I, and 29.3 kDa for CA II, respectively. CA IV was isolated from bovine lung
microsomes.
35
Initial rates of 4-nitrophenyl acetate hydrolysis were monitored spectrophotometrically, at
400 nm and 25C, with a Cary 3 apparatus interfaced with an IBM compatible PC by the method of
Pocker and Stone.. Solutions of substrate were prepared in anhydrous acetonitrile; the substrate
concentrations varied between 10 and 10 M. A molar absorption coefficient e 18,400 M.cm
was used for the 4-nitrophenolate formed by hydrolysis, in the conditions of the experiments (pH
7.80), as reported by Pocker and Stone. Non-enzymatic hydrolysis rates were always subtracted
from the observed rates. Duplicate experiments were done for each inhibitor, and the values
reported throughout the paper are the averages of such results. ICo represents the molarity of
inhibitor producing a 50% decrease of enzyme catalyzed hydrolysis of 4-nitrophenyl acetate.
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General procedure for the preparation of complexes 5- 17
An amount of 10 mM of sulfonamide 3 was dissolved in 50 mL of methanol-water (1:1, v/v). The
stoichiometric amount of metal salt dissolved in a small amount (5 mL) of water was added (a molar
ratio sulfonamide:metal salt of 1:1; 2:1 and 3:1 has been used in different experiments), and the
mixture was treated with the stoichiometric amount of KOH (in order to obtain the monopotassium
salt of the original sulfonamide) or with an excess of 25% acqueous amonia. The reaction mixture
Ia$ been heated on a steam bath for 1-3 hours, then left overnight and the obtained precipitates
were filtered and air dried. An exception from the above procedure was the preparation of complex
9, case in which trans-[Co.(en)Cl]CI has been used instead of a simple cobalt salt.
Results and Discussion
Complexes 5-17 prepared in the present study are shown in Table I, together with their
elemental analysis data.
Table I: Prepared complexes 5-17, containing the conjugate bases of sulfonamide 3 as ligand and
their elemental analysis data. L stands for the sulfonamide deprotonated species of 3, whereas tda
for the sulfonamide deprotonated species of 5-amino-l,3,4-thiadiazole-2-sulfonamide, the
hydrolysis product of 3.
No. Complex Analysis (calculated/found)
%M
a %C
b %H %N
5 K[VOL.] 4.3/4.5 16.4/16.1 1.3/1.3 9.1/1 9.0
6 [Fe(HL)CI] 8.7/8.5 15.0/14.8 1.5/1.6 17.5/17.5
7 [CoL(NH)] 9.7/10.0 15.8/15.4 2.3/2.2 23.1/23.0
8 [CoL(OH)](OH) 16.8/17.1 13.7/13.6 2.0/2.2 16.0/15.8
9 [CoLCI(OH)] 8.7/8.7 14.1/14.1 1.7/1.6 16.5/16.4
1 0 [CoL4(OH;)] 5.2/5.4 17.1/16.9 1.7/1.6 20.0/19.7
1 1 [NiL;z(NH3)] 9.7/9.4 15.8/15.8 2.3/2.6 23.1/23.0
1 2 [NiL(OH);] 9.6/9.6 15.7/15.8 1.9/1.5 18.4/18.3
1 3 [Cu(HL);Cl4] 20.9/20.5 12.2/11.9 1.2/1.3 14.3/14.1
1 4 [CuL(AcO);] 25.3/25.5 19.1/19.2 2.0/1.8 11.1/11.2
1 5 [Cu_L(AcO)2]n 25.3/25.1 19.1/18.9 2.0/2.1 11.1/10.8
1 6 [Cr(Htda)CI4(OH)] 16.2/16.2 7.5/7.5 1.5/1.3 17.4/17.5
1 7 [Cr(Htda)Cl]CI. 8 HO 7.8/7.9 7.2/7.1 3.6/4.0 6.8/16.5
By gravimetry; By combustion.
From the above data one can note several facts. Thus, although the synthesis have been
started from Fe(lll) and Co(Ill) salts (for preparing compounds 6 and 8, 9) the obtained derivatives
contained Fe(ll) and Co(ll) ions, respectively, due to reduction of the metal ions in the conditions
used in synthesis. This side reaction was anyhow of help, since Fe(ll) complexes of heterocyclic
sulfonamides have not been studied previously, in contrast to Fe(lll) complexes which were much
investigated.
.4 Synthesis in which ammonia has been used as deprotonating agent, led to the
formation of metal complexes in which this molecule was present in the coordination sphere, in
addition to the sulfonamide anion(s). The anion of the metal salt from which the complexes were
prepared was also of much importance in the synthesis, especially for the Co(ll) and Cu(ll)
derivatives, cases in which complexes with a large variety of compositions could be prepared by
slight variations of the synthetic procedure described above and the metal salt employed in the
preparations. In the case of the Cr(lll) derivatives, a hydrolysis of the original ligand was evidenced,
with formation of 5-amino-l,3,4-thiadiazole-2-sulfonamide (Htda) which subsequently complexed
(as neutral ligand) this metal ion. Such a behaviour was previously evidenced for the complexation
of divalent metal ions (such as Mg(ll) and Mn(ll)) by compound 3.
Electronic spectroscopic (by the diffuse reflectance technique) data for complexes 6-16
are shown in Tables II IV, together with the assignements of the observed transitions. For the V(IV)
complex .5 the typical transitions of V(IV) in square py.ramidal geometry were evidenced in the
37 electronic spectrum, at 26,315; 15,480 and 11,590 cm", respectively, whereas for the two Cr(lll)
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derivatives 16 and 17, the electronic spectral transitions are shown in Table IV, proving the
presence of octahedral chromium ions in these derivatives.
The electronic spectroscopic data for the Fe(ll), Co(ll) and Ni(ll) derivatives (Table II),
although generally more complicated than for the systems mentioned above, permitted to
evidence the presence of octahedral metal ions in many of the prepared complexes (such as 6, 7,
9-12), whereas for some Co(ll) derivatives (such as 8-10), tetrahedral geometries were also
found.39’4 Proposed geometries for some of these metal ions in the prepared complexes are
shown schematically below.
Table I1: Electronic spectroscopic data for compounds 6-12.
Compound
(colour)
6
(yellow)
Abs. max.
380
501
663
1055
Wavenumber
v (cm")
26,315
20,000
15,100
9,478
7
(pink)
8
(black)
9
(gray)
10
(pink)
11
(green)
12
(green)
38O
531
1111
380
490
6O8
1181
380
480
660
1250
38O
480
660
1250
380
428
638
819
1100
38O
625
740
1104
26,315
18,840
9,000
26,315
20,410
16,450
8,470
26,315
20,830
15,150
8,000
26,315
20,830
15,150
8,000
26,315
23,364
15,673
12,210
9,090
26,315
6,000
19,513
9,057
"CT charge transfer band.
Assignments
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Table II1: Electronic spectroscopic and room temperature magnetic data for complexes 13-15.
Complex
(colour)
13
(green)
14
(grayish-green)
1,5
(dark green)
(BM)
2.44
1.43
1.62
Wavenumber
v {cm1)
26,315
14,672
11,215
29,037
20,355
15,163
10,000
26,315
15,043
11,519
# CT charge transfer band.
Assignments
Table IV: Electronic spectroscopic data for the Cr(lll) complexes 16 and 17.
Complex
(colour)
16
(dark green)
17
(grayish-green)
Abs. max.
X(nm)
418
567
667
411
561
661
Wavenumber
v(cm)
23,930
17,640
14,995
24,330
17,825
15,130
Assignment
4A2g -->4Tlg
4A2g---B2g (D4h)
4A2a--.a,4Ea(D4h
4A2g _._),4T g
4A2g--->B2g (D4h)
4Ao4E(D4h)
CI NH3
NH
In the case of the copper complexes 13-15, the electronic spectroscopy gave very few
stereochemical information regarding the structure of the obtained compounds. Still, data of Table
III, correlated with the measured magnetic moments and EPR spectra, allowed us to propose some
hypothetical structures. Thus, the only Cu(ll) complex for which EPR signals were evidenced (at
room temperature, in powder) was 14, for which an isotropic EPR spectrum with g 2.0647 was
obtained. We hypothesize that this compound contains a Cu(ll) and a Cu(I) ion, and probably the
same is true for the polymeric derivative 1,5. The other obtained Cu(ll) derivative, 13, probably
contains Cu(ll)in trigonal bipyramidal geometry.
4 Since good crystals for X-ray crystallographic
experiments could not be obtained (mainly due to the extremely low solubility of the obtained
complexes in may solvents, excepting DMSO and DMF), all the structures proposed by us are
tentative, but they are based on data previously obtained by our and Borras’ group, by means of X-
ray crystallography.
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NH 3
OH NH
2 3
9 11
OH
Table V" IR, thermogravimetric and conductimetric data for compounds .5-17 and the original
ligands.
Compound IR Spectra ,cm TG an’lysis ConductimetrY
v(SO) v(SO)
as v(C=N) v(CO) v(M-X) calc./found AM (.0.
"1 x cm2x molq)
Htda 1170 1350 1610 d 0.9
3 1170 1350 1610 1720 d 0.8
,5 1170 1360 1610 1720 445 d 279
6 1170 1340 1600 1720 315, 390 d 3
7 1150 1360 1600 1720 510 5.6/5.8 9
8 1150 1370 1600 1720 420, 530 5.1/5.0 11
9 1175 1350 1590 1720 395, 470 5.3/5.2 298
10 1170 1340 1600 1720 420, 505 3.2/3.2 2
11 1150 1360 1575 1720 530 5.6/5.8
e 6
1 2 150 1355 1590 1720 435, 540 5.9/6.0 4
13 1150 1350 1600 1720 420, 520 d 2
14 1130 1360 1600 1695 310, 415 d 9
15 1145 1370 1595 1695 295, 430 d 3
16 1150 1350 1600 390 d 2
17 1140 1350 1600 450 21.7/21.4 114
In KBr; Weight loss between 70-190 C; Cl mM solution, in DMF, at 25C; No weight loss seen
under 250 C; Corresponding to 2NHa, lost at 135-150 C; Corresponding to 2HO (coordinated),
lost at 160-180 C; Corresponding to eight lattice water molecules lost at 70-110C.
Both complexes containing the sulfonamide-deprotonated species of sulfonamides 3 (L), as well
as complexes in which the free sulfonamide itself HL or its hydrolysis product, 5-amino-l,3,4-
thiadiazole-2-sulfonamide (Htda) act as ligands, have been prepared in the present study (Table I).
By comparing the IR spectra of the complexes and the corresponding ligands (Table V), the
following observations should be made" (i) the shift of the two sulfonamido vibrations (both the
symmetric as well as the the assymetric one), towards lower or higher wavenumbers in the spectra
of the complexes, as compared to the spectra of the corresponding ligand, as already documented
previously for similar complexes.’z This is a direct indication that the (deprotonated) sulfonamido
moieties of the ligands interacts with the metal ions in the newly prepared coordination
compounds; (ii) the amide vibrations (the most intense such bands at 1720 cm) of ligand 3 appear
unchanged in the IR spectra of complexes 5-13, suggesting that these moieties do not participate
in coordination of the metal ions. Still, this band is shifted at 1695 cm in the spectra of the two
copper complexes 14 and 15, probably due to participation of this moiety in coordination of the
metal ions (iii) the C=N stretching vibration in the spectra of the prepared complexes is shifted with
5-20 cm towards lower wavenumbers, as compared to the same vibration in the spectra of
sulfonamides 3 and Htda, indicating that one of the endocyclic nitrogens of the thiadiazolic ring
(presumably N-3) acts as donor atom, as already documented by X-ray crystallographic and
spectroscopic determinations on complexes of other sulfonamides (such as 1-3) with divalent
21 27 metal ions (Table V);’ (iv) changes in the region 3100-3160 cm, as the bands present in the
spectra of the original sulfonamides are present in the spectra of the prepared complexes too, but
they are not well resolved, and have a smaller intensity (data not shown). This is probably due to
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deprotonation of the SONH moiety and participation in the binding of cations; (v) the presence of
M-O, M-N or M-CI vibrations in the region between 295-550 cm.
Thermogravimetric analysis showed the presence of coordinated water/ammonia
molecules in some of the prepared complexes, which were lost in a single step, between 135-180
C, and of lattice water in the case of one complex, 17. All these compounds behaved as non-
electrolytes in DMF as solvent, except for 5 and 9 (2:1, and 1:2 electrolytes, respectively) and 17
(1:1 electrolyte) (Table V).
By correlating all the spectroscopic, magnetic, TG and conductimetric data, one can
conclude that ligand L (the conjugate base of sulfonamide 3) generally acts as a bidentate ligand in
the complexes prepared here, interacting with the metal ions by means of the sulfonamido and
endocyclic N-3 nitrogen atoms. An exception is the V(IV) derivative in which we consider L to act
monodentately, by means of the sulfonamidic nitrogen. When HL interacts with metal ions, the
donor system is probably similar to that of L, but the obtained complexes are generally much less
stable (data not shown). 5-Amino-l,3,4-thiadiazole-2-sulfonamide Htda also acts as a bidentate
ligand, by the same donor system as sulfonamide 3, similarly with the situation described before,
when the Mg(ll); Be(ll); Zn(ll); Cd(ll), Hg(ll) and Pb(ll) complexes of this sulfonamide have been
reported.
Table VI. CA inhibition data with the standard inhibitors 1-3, and the metal complexes 5-17 against
isozymes CA I, II and IV.
No Inhibitor K (nM)
hCA
a hCA II bCA IV
1 Acetazolamide 900 2 220
2 Benzolamide 780 4 240
3 LH 640 5.0 24
Htda 1550 230 780
.5 230 4.1 19
6 255 4.4 16
7 180 3.6 12
8 360 4.2 21
9 200 3.9 15
1 0 175 3.5 13
1 1 220 3.7 4
1 2 205 3.5 11
1 3 90 3.2 9
1 4 85 2.5 8
1,5 155 3.9 12
1 6 740 87 540
1 7 680 79 490
a Human (cloned)isozymes; From bovine muscle; From bovine lung microsomes.
The complexes ,5-17 together with the standard CA inhibitors 1-3 were assayed for
inhibition against four isozymes, hCA I, hCA II, and bCA IV (Table VI). As seen from the above data,
the chloracetamido derivative 3 is more inhibitory than acetazolamide, whereas the unacylated
compound Htda is less inhibitory than the above sulfonamides. The metal complexes ,5-17 are
much more inhibitory than the sulfonamides from which they derive 3, and Htda, and than all other
simple sulfonamides assayed. They behave similarly to the metal complexes of acetazolamide,
methazolamide or dorzolamide previously reported by this group, which were all more inhibitory
than the parent sulfonamide from which were prepared. ’=z Particularly strong inhibition was
observed for the Co(ll); Ni(ll) and Cu(ll) complexes, especially against CA II and CA IV, the isozymes
critical for aqueous humor formation.
The above differences of affinity for the different isozymes of the new inhibitors reported in
this paper, and the fact that the X-ray crystallographic structure of hCA IV has been recently
42 reported and became available in the Brookhaven Protein Database (in September 1997; file
code 1ZNC), prompted us to compare the tridimensional structure and active site architecture for
the three CA isozymes (CA I, II and IV) used in the present work (human and bovine CA IV
possess
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Fig. 1: hCA II with
the catalytically
critical Zn(II) ion
(central sphere) and
its three histidine
ligands (His 94, His
96 and His 119), as
well as the histidine
cluster evidenced.
The figure has been
generated by using
the programme
RasMol for
Windows 2.6 with a
Texas Instruments
4000 M PC, from
the X-ray
crystallographic
coordinates of
Hakansson et al.,
46
available from
Brookhaven Protein
Database (file code
2CBA).
Fig. 2: hCA I with
the catalytically
critical Zn(II) ion
(central sphere) and
its three histidine
ligands (His 94, His
96 and His 119), as
well as the active
site histidine
residues and Asp 4
evidenced. The figure
;" has been generated
,.,....*: by using the
/ programme RasMol
for Windows 2.6
"--;i with a Texas
Instruments 4000 M
PC, from the X-ray
crystallographic
coordinates of
Chakravarti and
Kannan
4-s available
from Brookhaven
Protein Database
(file code 1HUH).
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Fig. 3: hCA IV with
the catalytically
critical Zn(ll) ion
(central spheres)
and their three
histidine ligands
(His 94, His 96 and
His 119), as well as
the active site
residues His 64;
Cys 6; Cys 11G;
Cys 23 and Cys
203 evidenced.
Two
crystallographically
non-equivalent
protein molecules
are present in the
cell unit of hCA
IV.
42
very similar kinetic and inhibition susceptibility properties4) in order to explain their affinity for the
sulfonamide inhibitors reported by us here. Thus, Figs 1-3 show some active site residues known
43 46 to be important for catalysis in isozymes I, II and IV (the files 1HUH for hCA and 2CBA for hCA II
have been used, also available from Brookhaven Protein Database).
4a-4e
It has previously been proposed by us
4 that the high catalytic efficiency of the most active
isozyme, hCA II, is due to a unique feature of its active site: the presence of a histidine cluster,
consisting of the residues: His 64 two conformations; His 4 two conformations, His 3, His 10, His
15, His 17 (Fig. ).44 This cluster extends from the interior of the active site (His 64) to its entrance
(His 4 and His 3) till the surface of the protein (in the proximity of the active site entrance) and it
probably constitutes a very appropriate "channel" for efficiently transferring protons from the active
site to the reaction medium, but also for the binding of amphipatic compounds, such as the
44 47 sulfonamide inhibitors and their metal complexes. As seen from Fig. 2, in the low activity
isozyme hCA (which also binds sulfonamide/metal complexes of sulfonamide inhibitors with a 10-
;4 100 times lower affinity), such a cluster does not exist. Moreover, the pathways for the proton
transfer are somehow bifurcated and divergent as the four histidines present within the active site,
ie, His 64, 67, 200 and 243 (excepting, of course, for the three Zn(ll)ligands, which in all isozymes
are His 94, 96 and 119) are placed at bifurcating positions. As seen from Fig. 2, these four
histidines in hCA (His 64, His 67, His 200 and His 243) are rather buried in the active site so that,
probably, the proton transfer cannot be as efficient as the one assisted by the histidine cluster
present in HCA II, whereas inhibitors are probably unable to interact with them, as documented by
crystallographic studies of adducts of hCA with sulfonamides and anion inhibitors.
4 In this context
it is also enlightening that histamine, the first activator of hCA II for which the X-ray crystal structure
has recently been reported by this group,
44 which is able to enhance the catalytic efficiency of the
enzyme, does really bind in the region of the active site of hCA II containing the histidine cluster
shown in Fig. 1. In this context, we suggest a new hypothesis for explaining also differences of
affinity of the discussed CA isozymeS for the sulfonamide inhibitors and their metal complexes,
based on the interaction of inhibitors with the structural elements of the active site mentioned
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above. Indeed, for example in hCA II the amino acid residue in position 4 is His, whereas in hCA lit is
an Asp. This residue, situated just at the entrance within the active site, is a constituent of the
histidine cluster of isozyme I1. The negative charge of the carboxylate group of the Asp residue in
hCA probably influences its interaction with positive charges (such as the metal ions), present in
the complex inhibitors of the type described by us here. In fact many such compounds have a
higher affinity for hCA as compared to the parent, uncharged sulfonamides from which they were
obtained, presumably due to a supplementary interaction between this negative charge and the
cationic moiety of the inhibitor molecule.
In the case of hCA IV (Fig. 3) only one histidine residue is present within the active site, His
64, which as in hCA II, plays a critical role in catalysis, as proton shuttle residue between the active
site and the environment. But the most characteristic feature of the active site of this isozyme is
related to the presence of four cysteine residues, which form two disulfide bonds, situated at the
entrance within the active site cavity (Cys 6 Cys 11G, and Cys 23 Cys 203, respectively). These
residues occupy practically the same region of the active site as the histidine cluster in hCA II, and
we consider this as the most relevant aspect explaining the difference in affinity for sulfonamide
inhibitors of the two isozymes. The hypothesis of Stams et al." that it is the residue 131 (a valine in
hCA IV and a phenylalanine in hCA II) which is responsible for the above mentioned differences,
seems to us very unrealistic, since this residue is situated relatively far away from the active site, and
could account for such a difference in affinity only for inhibitors with an extremely long and flexible
molecule.
In conclusion, in this paper we present novel types of very potent CA inhibitors from the
class of the metal complexes of heterocyclic sulfonamides, together with a new hypothesis to
explain the different affinity of such inhibitors for the physiologically relevant isozymes CA I, II and
IV.
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